BD is splitting its Biosciences and Diagnostic Solutions division into a standalone entity to sharpen focus on high-growth MedTech sectors like connected care and biopharma systems. The spin-off, slated for completion by 2026, aims to unlock value through specialized R&D investments and streamlined operations
